Streetbeat News

TRDA

Entrada Therapeutics, Inc.

https://www.entradatx.com

Industry

Biotechnology

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Open

10.63

Mkt cap

406M

Volume

73K

High

10.81

P/E Ratio

6.43

52-wk high

21.79

Low

10.61

Div yield

N/A

52-wk low

10.15

Entrada Therapeutics, Inc. (TRDA) reported Q4 earnings of $0.03 per share, surpassing the Zacks Consensus Estimate of a loss of $0.66 per share. This marks a significant improvement from the loss of $0.29 per share a year ago.

Portfolio Pulse from

February 27, 2025 | 2:45 pm

Entrada Therapeutics reported its Q4 and full-year 2024 financial results, highlighting FDA and MHRA authorizations for clinical trials and a strong cash position expected to last into Q2 2027.

Portfolio Pulse from

February 27, 2025 | 12:15 pm

Entrada Therapeutics is advancing its Endosomal Escape Vehicle platform to address intracellular drug delivery challenges. With $449.3 million in reserves and strategic partnerships, the company is financially stable until 2027. Its ENTR-601-44 drug for Duchenne muscular dystrophy is entering critical trials, potentially validating its platform and capturing market share.

Portfolio Pulse from

February 19, 2025 | 4:45 pm

Entrada Therapeutics (TRDA) is highlighted as a strong investment opportunity due to its recent price strength, making it appealing for investors seeking fundamentally strong stocks.

Portfolio Pulse from

December 11, 2024 | 3:00 pm

Entrada Therapeutics (TRDA) is highlighted as a promising option for trend investors due to its recent price trend and strong fundamentals. It has been identified through a short-term trading strategy screen.

Portfolio Pulse from

November 25, 2024 | 3:00 pm

Entrada Therapeutics presented positive clinical and preclinical data at the World Muscle Society Congress, supporting its Duchenne franchise. The data reinforces the safety of ENTR-601-44 and supports upcoming regulatory filings for Phase 2 trials.